Adli M, Ruxh AJ, Möller HJ, Bauer M.
(2003). Algorithms for optimizing the treatment of depression :
making the right decision at the right time. Pharmacopsychiatry;36 (suppl.3)
Aman, M.G., De Smedt, G., Derivan, A., Lyons, B., Findling,
R.L. (2002). Double-Blind, Placebo-Controlled Study of
Risperidone for the Treatment of Disruptive Behaviors in
Children With Subaverage Intelligence. American Journal of
Psychiatry, 159, 1337-1346.
Arnsten A.F.T. (2000) Genetics of Chidhood disorders: XVIII.
ADHD, Part 2: Norepinephrine Has a Critical Modulatory
Influence on Prefrontal Cortical Function. Journal of the
American Academy of Child and Adolescent Psychiatry,
39(9), 1201-1205.
Association des pharmaciens du Canada (2008). Compendium
des produits et spécialités pharmaceutiques. 2627p. ISBN
1-894402-14-6 (édition 2008).
Avis
de la FDA concernant l’atomoxétine
Avis
du Conseil québécois du médicament concernant
l’Adderal
Avis
du Conseil québécois du médicament concernant le
Concerta
Baillargeon, J., Contreras, S., Grady, J. J., Black, S. A.,
and Murray, O. (2000). Compliance with antidepressant
medication among prison inmates with depressive disorders.
Psychiatric Services, 51(11), 1444-1446.
Barkley A.R. (2000) Genetics of the Childhood Disorders:
XVII. ADHD, Part 1: The Executive Functions and ADHD.
Journal of the American Academy of Child and Adolescent
Psychiatry, 39(8), 1064-1070.
Bastiaens L. (1995). Compliance with pharmacotherapy in
adolescents : effects of patients’ and parents’
knowledge and attitudes toward treatment. Journal of child
and adolescent psychopharmacology, 5(1), 39-48.
Baumann, M. and Trincard, M. (2002). [Autonomy attitudes in
the treatment compliance of a cohort of subjects with
continuous psychotropic drug administration]. Encephale,
28(5 Pt 1), 389-396.
Becker, M. H. Sociobehavioral Determinants of Compliance.
In : Sackett D., Haynes R. B. (1976). Compliance with
Therapeutic Regimens. Baltimore and London: Johns Hopkins
University Press, 40-50.
Becker, M.H. and Mainman, L.A. (1975). Sociobehavioral
Determinants of Compliance with Health and Medical Care
Recommendations. Medical Care, 13(1), 10-24.
Ben Amar, Maxime. La polyconsommation de psychotropes et les
principales interactions pharmacologiques associées. Le comité
permanent de lutte à la toxicomanie, octobre 2004;185p. ISBN :
2-551-22545-0.
Bezchlibnyk-Butler, K.Z. et A.S. Virani (2007). Clinical
handbook of psychotropic drugs for children and
adolescents. Cambridge MA: Hogrefe & Huber
Publisher
Biederman, J.; Wilens, T.; Mick, E.; Spencer, T., and
Faraone, S. V. (1999) Pharmacotherapy of
attention-deficit/hyperactivity disorder reduces risk for
substance use disorder. Pediatrics, 104(2), e20.
Britten, N. (1998). Psychiatry, stigma, and resistance.
Psychiatrists need to concentrate on understanding, not simply
compliance. British Medical Journal, 317(7164),
963-964.
Buck, M.L. (2002) New Agents and Second-line Therapies for
ADHD. Pediatric Pharmacology, 8(4).
Bush,
P.J., Iannotti, R.J. (1990). A Children's Health Belief
Model. Medical Care, 28(1), 69-86.
Cabib, S., Puglisi-Allegra, S., Ventura, R. 2002) The
contribution of comparative studies in inbred strains of mice
to the understanding of the hyperactive phenotype.
Behavoural Brain Research, 130, 103-109.
Clinical Pharmacology
database.
Chevalier, R., Sylvestre, A., Fillion, I. et Jérome, M.
(2005). Logiciel informatique Vigilance Santé –
Version août 2005.
Connor, D.F., Fletcher, K.E., Swanson, J.M. (1999) A
Meta-Analysis of Clonidine for Symptoms of Attention-Deficit
Hyperactivity Disorder. Journal of the American Academy of
Child and Adolescent Psychiatry, 38(12), 1551-1559.
Conrad, P. (1985). The meaning of medications : another look
at compliance. Social Sciences and Medicine, 20(1),
29-37.
Cramer, J. A., & Rosenheck, R. (1998). Compliance with medication regimens for mental and physical disorders. Psychiatric Services, 49, 196-201.
Davis, M.S. Variations in patients' compliance with doctors'
advice: an empirical analysis of patterns of communication.
(1968). American Journal of Public Health & the
Nation's Health, 58(2), 274-288.
DiMatteo, M. R. (1994). Enhancing patient adherence to
medical recommendations. JAMA: Jan 5, 271(1), 79.
Dixon, L., Weiden, P., Torres, M., and Lehman, A. (1997).
Assertive community treatment and medication compliance in the
homeless mentally ill. American Journal of Psychiatry,
154(9), 1302-1304.
dos Reis, S., Zito, J.M., Safer, D.J., Soeken, K.L.,
Mitchell, J.W. Jr., Ellwood, L.C. (2003). Parental
perceptions and satisfaction with stimulant medication for
attention-deficit hyperactivity disorder. Journal of
Developmental and Behavioral Pediatrics, 24(3),
155-162.
Ellis, S. Shumaker S. Sieber W. Rand C. (2000). Adherence to
pharmacological interventions. Current trends and future
directions. The Pharmacological Intervention Working Group.
Controlled Clinical Trials, 21(5 Suppl), 218S-225S.
Faraone, S. V.; Biederman, J., and Roe, C. (2002)
Comparative efficacy of Adderall and methylphenidate in
attention- deficit/hyperactivity disorder: a meta-analysis.
Journal of Clinical Psychopharmacology, 22(5),
468-473.
Fawcett, J. et Kupfer, D. (1995). Compliance: Definitions and key issues. Journal of Clinical Psychiatry, 56, 4-8.
Findling, R.L., Maxwell, K., Wiznitzer, M. (1997). An Open
Clinical Trial of Risperidone Monotherapy in Young Children
With Autistic Disorder. Psychopharmacology Bulletin,
33(1), 155-159.
Findling R.L., McNamara NK, Branicky L.A., Schluchter M.D.,
Lemon E., Blumer J.L. (2000 ). A double-blind pilot study of
risperidone in the treatment of conduct disorder. Journal
of the American Academy of Child and Adolescent Psychiatry,
39(4),509–516
Garant M. (1999). Les interactions médicamenteuses.
Bulletin d’information du département de pharmacie,
Hôpital Robert Giffard. Vol 16, no 6. Novembre
1999.
Ghaziuddin, N., King, C.A., Hovey, J.D., Zaccagnini, J.,
Ghaziuddin, M. (1999). Medication
noncompliance in adolescents with psychiatric disorders. Child Psychiatry and Human Development, 30(2),
103-110.
Glick, I.D., Murray, S.R., Vasudevan, P., Marder, S.R., Hu,
R.J. (2001). Treatment with atypical antipsychotics: new
indications and new populations. Journal of Psychiatric
Research, 35, 187–191
Grasset, F., Bonvin, E., and Pomini, V. (2000).
[Psychotropic pharmacotherapy, treatment compliance and
prescription observance]. Revue Médicale de la Suisse
Romande, 120(2), 137-143.
Greenhill, L.L., Setterberg, S. (1993). Pharmacotherapy of
disorders of adolescents. Psychiatric Clinics of North
America, 16(4), 793-814.
Hack, S., Chow, B. (2001). Pediatric psychotropic medication
compliance: a literature review and research-based suggestions
for improving treatment compliance. Journal of Child and
Adolescent Psychopharmacology, 11(1), 59-67.
Haynes, R.B. (1979). Introduction. In: Haynes, R.B., Taylor,
D.W. and Sackett, D.L. (Eds.), Compliance in Health
Care. Baltimore: Johns Hopkins University Press, 1-7.
Horne, R., Weinman, J. (1999). Patients’ beliefs about
prescribed medicines and their role in adherence to treatment
in chronic physical illness. Journal of Psychosomatic
Research, 47(6), 555-567.
Joffe, R. T., Gardner, D.M. et S.P. Kutcher (2002).
Guide des médicaments psychotropes (2e édition).
Markham ON: MDH Consulting Inc.
Ketter TA, Wang PW, Becker OV, Nowakowska C, Yang YS. (2003)
The diverse roles of anticonvulsivants in bipolar disorders.
Ann Clin Psychiatry, Jun;15(2) :95-108.
Kirkwood CK. (2003). Anxiety disorders. Dans : Dipiro JT,
Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, (Eds),
Pharmacotherapy : A pathophysiologic approach (p.
1182-1196). Appleton and Lange, 2003,
Korsch, B.M., Gozzi, E.K., Francis, V. (1968). Gaps in
doctor-patient communication. Pediatrics, 42,
855-871.
Léonard L. et Ben Amar M. (2002). Les Psychotropes :
pharmacologie et toxicomanie. Québec, Presses de
l’Université de Montréal, 894p.
Lerner, B.H. (1997). From careless consumptives to
recalcitrant patients: the historical construction of
non-compliance. Social Sciences and Medicine, 45(9),
1423-1431.
Madras, B. K. ; Miller, G. M., and Fischman, A. J. (2002)
The dopamine transporter: relevance to attention deficit
hyperactivity disorder (ADHD). Behavioural Brain Research,
130(1-2), 57-63.
Maranda F, & Garel P. (2004). La prescription d’un
antidépresseur à un adolescent peut-elle encore se justifier?
MedActuel FMC, 14 avril 2004 : 22-23.
Marsolais, G. (2004). Petit guide des médicaments en
santé mentale à l’intention des intervenants d’aide
en situation de crise.
Masellis, M.; Basile, V. S.; Muglia, P.; Ozdemir, V.;
Macciardi, F. M., and Kennedy, J. L. (2002) Psychiatric
pharmacogenetics: personalizing psychostimulant therapy in
attention-deficit/hyperactivity disorder. Behavioural Brain
Research, 130(1-2), 85-90.
Meichenbaum, D., & Turk, D.C. (1987). Facilitating
treatment adherence. New-York: Plenum Press.
McDonald, H. P., Garg, A. X., & Haynes, R. B. (2002). Interventions to enhance patient adherence to medication prescriptions: Scientific review. Journal of the American Medical Association, 288, 2868-2879.
McDougle, C.J., Holmes, J.P., Bronson, M.R., Anderson, G.M.,
Volkmar, F.R., Price, L.H., Cohen, D.J.(1997). Risperidone
treatment of children and adolescents with pervasive
developmental disorders: a prospective open-label study.
Journal of the American Academy of Child and Adolescent
Psychiatry, 36 (5), 685–693.
Meichenbaum, D., & Turk, D. C. (1987). Facilitating treatment adherence. New York : Plenum Press.
Mercier, C. (1989). Le rôle des facteurs subjectifs dans la
fidélité à la médication. Revue canadienne de psychiatrie,
34, 662-667.
McDonald, H.P., Garg, A.X., Haynes, R.B. (2002) Interventions
to enhance patient adherence to medication prescriptions:
scientific review. JAMA, 288(22), 2868-2879.
Nicolson, R., Awad, G., Sloman, L. (1998) An open trial of
risperidone in young autistic children. Journal of the
American Academy of Child and Adolescent Psychiatry,
37(4),372–376.
Oades, R. D. (2002) Dopamine may be 'hyper' with respect to
noradrenaline metabolism, but 'hypo' with respect to serotonin
metabolism in children with attention- deficit hyperactivity
disorder. Behavioural Brain Research, 130(1-2),
97-102.
Pappadopulos E., Macintyre J.C., Crismon M.L., Findling
R.L., Malone R.P., Derivan A., Schooler, N., Sikich, L.,
Greenhill, L., Schur, S.B., Felton, C.J., Kranzler, H., Rube,
D.M., Sverd, J., Finnerty, M., Ketner, S., Siennick, S.E.,
Jensen, P.S. (2003). Treatment recommendations for the use of
antipsychotics for aggressive youth (TRAAY) Part II.
Journal of the American Academy of Child and Adolescent
Psychiatry, 42(2), 145–161
Prévenir le syndrome sérotoninergique (2003). Le médecin du Québec,
38 (8):131,133.
Reesal, RT. (1999). Antidepressant Discontinuation Syndrome.
Canadian journal of Diagnosis, nov. 1999, 119-125.
Rosenbaum, J.F. Perspectives on ADHD. From the 154th Annual
Meeting of the American Psychiatric Association; May 5-10,
2001; New Orleans, Louisiana.
Ross, F.M. (1991). Patient compliance – Whose
responsibility? Social Sciences and Medicine, 32(1),
89-94.
Schur, S.B., Sikich, L., Findling, R., Malone, R., Crismon,
M., Derivan, A., MacIntyre, J., Pappadopulos, E., Greenhill,
L., Schooler, N., Van Orden, K., Jensen, P. (2003) Treatment
recommendations for the use of antipsychotics for aggressive
youth (TRAAY). Part I: Review of relevant literature.
Journal of the American Academy of Child and Adolescent
Psychiatry, 42(2), 132-144.
Sleath, B., Roter, D., Chewning, B., Svarstad, B. (1999). Asking
questions about medication: analysis of physician-patient
interactions and physician perceptions. Medical Care,
37(11), 1169-1173.
Sleator, E.K. (1985). Measurement of compliance.
Psychopharmacology Bulletin, 21(4), 1089-1093.
Snyder, R., Turgay, A., Aman, M., Binder, C., Fisman, S.,
& Carrolle, A. (2002). Effects of risperidone on conduct
and disruptive behavior disorders in children with subaverage
IQs. Journal of American Academy of Child and Adolescent
Psychiatry, 41(9), 1026–1036.
Sonuga-Barke, E. J. (2002) Psychological heterogeneity in
AD/HD--a dual pathway model of behaviour and cognition.
Behavioural Brain Research, 130(1-2), 29-36.
Stern P.H., Garg A., Stern T.P. (2002) When Children with
Attention-Deficit/Hyperactivity Disorder Become Adults.
South Medicine Journal, 95(9), 985-991.
Swanson, J. M. and Volkow, N. D. (2002) Pharmacokinetic and
pharmacodynamic properties of stimulants: implications for the
design of new treatments for ADHD. Behavioural Brain
Research, 130(1-2), 73-78.
Syndrome
sérotoninergique, site de Santé Canada
Syndrome
de discontinuation, site de Santé Canada
Therapeutic Research Center. Pharmacist’s
Letter. Numéros de janvier à août 2005.
Thiruchelvam, D., Charach, A., Schachar, R. J. (2001).
Moderators and Mediators of Long-Term Adherence to Stimulant
Treatment in Children With ADHD. Journal of the American
Academy of Child and Adolescent Psychiatry, 40(8),
922-928.
Trostle, J.A., (1998). Medical Compliance as an Ideology.
Social Sciences and Medicine, 27(12), 1299-1308.
Wilens, T. E.; Faraone, S. V.; Biederman, J., and
Gunawardene, S. (2003). Does stimulant therapy of
attention-deficit/hyperactivity disorder beget later substance
abuse? A meta-analytic review of the literature. Pediatrics,
111(1), 179-185.
Weiden, P. J., Matt, T., Curcia, N. (1995). Recognition and
Management of Neuroleptic Noncompliance in Contemporary Issues
in the Treatment of Schizophrenia. In Christian L. Shriqui and
Henry A. Nasrallah. (Eds.), Contemporary Issues in the
Treatment of Schizophrenia. 1st edition. 863 p.
Willey, C., Redding, C., Stafford, J., Garfield, F.,
Geletko, S., Flanigan, T., Melbourne, K., Mitty, J., and Caro,
J. J. (2000). Stages of change for adherence with medication
regimens for chronic disease: development and validation of a
measure. Clinical Therapy, 22(7), 858-871.
Williams, R. A., Hollis, H. M., and Benoit, K. (1998).
Attitudes toward psychiatric medications among incarcerated
female adolescents. Journal of the American Academy of
Child and Adolescent Psychiatry, 37(12), 1301-1307.
Zanarini MC. (2004). Update on Pharmacotherapy of Borderline
Personality Disorder.Current psychiatry reports 2004,
6: 66-70.
|